Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection
- PMID: 3025881
- PMCID: PMC304252
- DOI: 10.1073/pnas.84.2.570
Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection
Abstract
Five distinct Epstein-Barr virus (EBV)-determined nuclear antigens (EBNA-1 to EBNA-5) were recently identified. Antibody responses to these antigens could conceivably differ, and thus prove of serodiagnostic value, in EBV-associated disease processes. As a first step, murine or human cell lines transfected with appropriate EBV DNA fragments and stably expressing either EBNA-1 or EBNA-2 were used to determine the frequency and time of emergence of antibodies to these two antigens in the course of acute and chronic infectious mononucleosis (IM) and to assess their titers in so-called chronic active EBV infections. Following IM, antibodies to EBNA-2 arose first and, after reaching peak titers, declined again in time to lower persistent or even nondetectable levels. Antibodies to EBNA-1 emerged several weeks or months after anti-EBNA-2 and gradually attained the titers at which they persisted indefinitely. The ratios between the anti-EBNA-1 and anti-EBNA-2 titers therefore were generally well below 1.0 during the first 6-12 months after IM and turned to well above 1.0 during the second year. In clear cases of chronic IM, the inversion of this ratio was delayed or prevented. In the less well-defined chronic EBV infections, low ratios were observed in only some of the patients. Because many of these illnesses were not ushered in by a proven IM and often showed EBV-specific antibody profiles within the normally expected range, a causal role of the virus in these cases remains doubtful.
Similar articles
-
Relationship between clinical stage, histopathology and antibody titers against the second Epstein-Barr virus nuclear antigen (EBNA-2) in non-Hodgkin's lymphoma patients.Int J Cancer. 1989 Jun 15;43(6):1017-21. doi: 10.1002/ijc.2910430610. Int J Cancer. 1989. PMID: 2543639
-
Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.Brain. 2024 Oct 3;147(10):3573-3582. doi: 10.1093/brain/awae110. Brain. 2024. PMID: 38630618 Free PMC article.
-
Immune response to Epstein-Barr virus (EBV) in ataxia-telangiectasia: EBV-specific antibody patterns and their relation to cell-mediated immunity.Kroc Found Ser. 1985;19:287-300. Kroc Found Ser. 1985. PMID: 2999343
-
T cell recognition of Epstein-Barr virus associated lymphomas.Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
-
Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.J Clin Immunol. 1984 Sep;4(5):369-82. doi: 10.1007/BF00917140. J Clin Immunol. 1984. PMID: 6092413 Review.
Cited by
-
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.Leuk Lymphoma. 2013 Nov;54(11):2571-3. doi: 10.3109/10428194.2013.796048. Epub 2013 Jun 3. Leuk Lymphoma. 2013. PMID: 23597143 Free PMC article. No abstract available.
-
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.Vaccines (Basel). 2021 Nov 7;9(11):1290. doi: 10.3390/vaccines9111290. Vaccines (Basel). 2021. PMID: 34835222 Free PMC article. Review.
-
Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection.Arch Virol. 1996;141(5):857-64. doi: 10.1007/BF01718160. Arch Virol. 1996. PMID: 8678831
-
Infectious Mononucleosis.Curr Top Microbiol Immunol. 2015;390(Pt 1):211-40. doi: 10.1007/978-3-319-22822-8_9. Curr Top Microbiol Immunol. 2015. PMID: 26424648 Free PMC article. Review.
-
Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies.Eur J Pediatr. 1992 Nov;151(11):794-8. doi: 10.1007/BF01957926. Eur J Pediatr. 1992. PMID: 1334834 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials